1. Malý J et al. Changes in hemostasis in malignant diseases. Vnitrini Lekarstvi 2002; 48: 614-8.
2. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010; 102: 2–9.
3. S. Fisch. Thrombose und Krebs. Österreichische Ärztezeitung 2014. 11.
4. Khorana AA et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-4.
5. Massicotte MP et al. Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 98; 133: 770-6.
6. Raffini L et al. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124: 1001-8.
7. Sandoval JA et al. Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: An increasing population at risk. J Vasc Surg 2008; 47: 837-43.
8. Piovesan D et al. Epidemiology of venous thrombosis in children with cancer. Thrombosis Heamostasis 2014; 111: 1015-21.
9. Athale U et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008; 51: 792-7.
10. Wiernikowski JT, Athale UH. Thromboembolic complications in children with cancer. Thromb Res 2006; 118: 137-52.
11. Lipay NV et al. Epidemiology of venous thromboembolism in children with malignant diseases: A single-center study of the Belarusian Center for Pediatric Oncology and Hematology. Thrombosis Res 2011; 128: 130-4.
12. Nowak-Göttl U et al. Thrombosis in childhood acute lymphoblastic leukaemia: Epidemiology, aetiology, diagnosis, prevention and treatment. Best Practice & Res. Clin Heamatol 2009; 22: 103-14.
13. Athale U et al. Thromboembolism in children with sarcoma. Pediatr Blood Cancer 2007; 49: 171-6.
14. Paz-Priel I et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007; 25: 1519-24.
15. Lesley G. Mitchell et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508-16.
16. Ghanem KM et al. Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management. Pediatr Blood Cancer 2017 Dec; 64 [Prepub ahead of print, DOI 10.1002/pbc.26694].
17. Walker AJ et al. Venous thromboembolism in children with cancer - a population-based cohort study. Thromb Res 2014; 133: 340-4.
18. Caruso V et al. Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216-22.
19. Kaste SC et al. Pilot study of noninvasive detection of venous occlusions from central venous access devices in children treated for acute lymphoblastic leukemia. Pediatr Radiol 1999; 29: 570-4.
20. Mitchell LG et al. Hemostasis in childhood acute lymphoblastic leukemia: Coagulopathy induced by disease and treatment. Semin Thromb Haemost 1995; 21: 390-401.
21. Nowak-Göttl U et al. The course of fibrinolytic proteins in children with malignant bone tumours. Eur J Pediatr 1999; 158 (Suppl 3): 151-3.
22. Benns M et al. Soft tissue sarcomas may present with deep vein thrombosis. J Vasc Surg 2006; 43: 788-93.
23. Damron TA et al. Risk of venous thromboembolism in bone and soft-tissue sarcoma patients undergoing surgical intervention: A report from prior to the initiation of SCIP measures. J Surg Oncol 2011; 103: 643-7.
24. Georgopoulos G et al. Incidence of deep vein thrombosis and pulmonary embolism in the elective pediatric orthopaedic patient. J Pediatr Orthop 2016; 36: 101-9.
25. Deitcher SR et al. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004; 145: 848-50.
26. Wells EM, Packer RJ. Pediatric brain tumors. Continuum (Minneap Minn) 2015. (2. Neuro-oncology). 373-96.
27. Tabori U et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004; 43: 633-6.
28. Semrad TJ et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106: 601-8.
29. Athale UH, Chan AK. Thromboembolic complications in pediatric hematologic malignancies. Semin Thromb Haemost 2007; 33: 416-26.
30. Spavor M et al. Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model. Thromb Res 2016; 144: 27-31.
31. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Critical Rev Haematol/Oncol 1998; 28: 97-113.
32. Mitchell L et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis Heamostasis 2003; 90: 235-44.
33. Bushman JE et al. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000; 24: 559-65.
34. Mitchell LG et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Hematology/Oncology 1994; 16: 120-6.
35. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: Effects of the disease and therapy. Thromb Res 2003; 111: 199-212.
36. Mitchell L et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: Results of a multicenter cohort study. Blood 2010; 115: 4999-5004.
37. Nowak-Göttl U et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): Prednisone versus dexamethasone administration. Blood 2003; 101: 2529-33.
38. Nowak-Göttl U et al. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica 1996: 81: 127-31.
39. Duval M et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734-9.
40. Revel-Vilk S et al. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer 2010; 116: 4197-205.
41. Ko RH, Thornburg CD. Venous thromboembolism in children with cancer and blood disorders. Front Pediatr 2017; 5: 12.
42. Glaser DW et al. Catheter-related thrombosis in children with cancer. J Pediatr 2001; 138: 255-9.
43. Farinasso L et al. Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: A prospective study. Leukemia 2007; 21: 552-6.
44. Kreuz W et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome. Results of a multicenter study. Arterioscler Thromb Vasc Biol 2006; 26: 1901-6.
45. Monagle P et al. Antithrombotic therapy in children. Chest 2001; 119: 344-70.
46. Monagle P et al. Fibrinolytic system in adolescents: Response to venous occlusion stress tests. Pediatr Res 2003; 53: 333-7.
47. Eber SW et al. Praxisorientierte Diagnostik und Therapie bei Thrombophilie und Thrombosen im Kindes- u. Jugendalter. Kinder- und Jugendmedizin 2012; 12: 234-7.
48. Nowak-Göttl U et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595-9.
49. Giordano P et al. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Haematol 2010; 85: 325-30.
50. Tullius BP et al. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: Guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16: 175-80.
51. Polen E et al. Post-thrombotic syndrome after central venous catheter removal in childhood cancer survivors: A prospective cohort study. Pediatr Blood Cancer 2015;. 62: 285-90.
52. Kuhle S et al. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost 2008; 6: 589-94.
53. Athale U et al. Thromboembolism in children with lymphoma. Thromb Res 2008; 122: 459-65.
54. Ranta S et al. Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. Br J Haematol 2015; 168: 547-52.
55. Ilie M et al. Use of circulating tumor cells in prospective clinical trials for NSCLC patients - standardization of the pre-analytical conditions. Clin Chem Lab Med 2018, Feb 3 [Prepub ahead of print, DOI 10.1515/cclm-2017-0764].